Digital Diagnostics

The Digital Diagnostics product training page provides access to assigned courses.

LumineticsCore (formerly IDx-DR) is intended for healthcare providers to automatically detect more than mild diabetic retinopathy in adults aged 22 or older with diabetes and no prior diabetic retinopathy diagnosis. It is indicated for use with the Topcon NW400.

LumineticsCore is an AI diagnostic system that autonomously diagnoses diabetic retinopathy, including macular edema, and provides results at the point of care.

Digital Diagnostics says it was the first company to receive FDA clearance for an AI diagnostic platform that makes diagnoses without physician input.

The pilot study compares the IDx-DR and Retinalyze AI algorithms for diabetic retinopathy screening and examines their effectiveness, accuracy, and potential applications.

The study compares autonomous AI-based screening with human-graded ultra-widefield color fundus images for early diabetic retinopathy staging in asymptomatic patients.

Digital Diagnostics provides digital media resources, including videos and infographics, about diagnostic healthcare technologies and patient care.

Digital Diagnostics lists upcoming diagnostic healthcare events, including conferences, webinars, and workshops featuring industry experts and technologies related to medical imaging and patient care.

Digital Diagnostics lists featured and other open positions and says its goal is to transform healthcare through intelligent automation.

The page discusses differences between autonomous and assistive AI in healthcare and argues that autonomous AI, such as Digital Diagnostics’ FDA-cleared AI, can support scalable value and improved outcomes.

Digital Diagnostics develops FDA-cleared autonomous AI for diagnostic care.

Digital Diagnostics says it builds healthcare solutions around ethical principles of AI.

The page offers a form to request information about Digital Diagnostics and its products.

Digital Diagnostics provides product support by email at support@digitaldiagnostics.com or through its help center; the support team says it will respond within one business day.

Digital Diagnostics says its FDA-cleared technology includes the first autonomous AI for diabetic retinopathy and is intended to enhance clinical accuracy, patient outcomes, and health equity.

Digital Diagnostics Inc. says it is committed to protecting personal information and addresses its collection, use, and retention.